Alliances
Agreement will address limitations in development of multiplex point-of-care Lateral Flow Assay diagnostic tests
Oncoceutics, Inc., announced a collaboration with the National Cancer Institute funded Pediatric Preclinical Testing Consortium to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas.
Sosei Group Corporation inked a strategic multi-target partnership with Takeda Pharmaceutical to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor targets. The initial focus will be on gastrointestinal targets.
Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group.
Supporting rare disease diagnosis, education, and clinical research
Under the terms of the deal, Exelixis is paying Aurigene $10 million up front for exclusive options to license three existing programs. The two companies will then launch three drug discovery programs led by Aurigene on mutually agreed-upon targets.
First major drug development agreement signed by Sensyne Health since IPO with potential for expansion
Under the terms of the deal, RegenxBio granted Pfizer a non-exclusive global license, with rights to sublicense, RegenxBio’s NAV AAV9 vector. In return, Pfizer is paying RegenxBio an upfront payment, various milestones and royalties on net sales.
hematologists and multiple myeloma patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the diagnostic service provided by Everything Genetic Ltd. SkylineDx, the diagnostics company that developed the test, announced its collaboration with the UK based provider of a genetic testing service.
The deal is designed to accelerate Avalon’s standardization, automation and bio-production for CAR-T cells and other cellular therapies related to immunotherapy.
PRESS RELEASES